AstraZeneca Annual Report and Financial Statements Form 20-F Information 2003 77 9 Tangible fixed assets Assets in Total Land and Plant and course of tangible buildings equipment construction assets $m $m $m $m Cost At beginning of year 3,145 6,600 1,298 11,043 Exchange adjustments 448 904 133 1,485 Capital expenditure 67 208 964 1,239 Transfer of assets into use 510 915 1,425 Disposals and other movements 42 663 22 727 At end of year 4,128 7,964 948 13,040 Depreciation At beginning of year 895 3,551 4,446 Exchange adjustments 129 529 658 Charge for year 150 836 986 Disposals and other movements 35 551 586 At end of year 1,139 4,365 5,504 Net book value at 31 December 2003 2,989 3,599 948 7,536 Net book value at 31 December 2002 2,250 3,049 1,298 6,597 Capital expenditure in the year of $1,239m 2002 $1,342m did not include any capitalised finance leases 2002 $nil.
Cash expenditure on tangible fixed assets was $1,282m 2002 $1,340m, 2001 $1,385m.
2003 2002 $m $m The net book value of land and buildings comprised Freeholds 2,956 2,220 Long leases over 50 years unexpired 32 29 Short leases 1 1 2,989 2,250 10 Goodwill and intangible assets Intangible Goodwill assets Total $m $m $m Cost At beginning of year 1,102 3,117 4,219 Exchange adjustments 52 474 526 Additions 1 112 113 Disposals and other movements 81 81 At end of year 1,155 3,622 4,777 Amortisation At beginning of year 249 1,163 1,412 Exchange adjustments 14 238 252 Charge for year 59 245 304 Disposals and other movements 75 75 At end of year 322 1,571 1,893 Net book value at 31 December 2003 833 2,051 2,884 Net book value at 31 December 2002 853 1,954 2,807
